Literature DB >> 1537377

Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen.

P Lastres1, T Bellon, C Cabañas, F Sanchez-Madrid, A Acevedo, A Gougos, M Letarte, C Bernabeu.   

Abstract

Endoglin is an endothelial homodimeric membrane antigen containing the tripeptide arginine-glycine-aspartic acid (RGD), which is a recognition motif for adhesion receptors of the integrin family. We have investigated the expression of endoglin by monocyte/macrophage cells from different tissue compartments and at different stages of cell differentiation. Although endoglin is absent from peripheral blood monocytes, it is expressed by in vitro differentiated monocytes as determined by flow cytometry using the endoglin-specific monoclonal antibody 44G4 and 8E11. Furthermore, Northern blot analyses revealed a correlation between the presence of endoglin mRNA and the surface expression of the antigen by in vitro differentiated monocytes. Immunostaining of frozen tissue sections with the 8E11 monoclonal antibody demonstrated the presence of endoglin not only in the endothelium of all the tissues studied, but also on the interstitial macrophages present in the red pulp of the spleen. Using as a model of macrophage differentiation monocytic cell lines treated with phorbol esters, we found that the reactivity of the 8E11 monoclonal antibody is greatly increased on U-937 and HL-60 cells during their PMA-induced differentiation. These findings clearly demonstrate for the first time the regulated expression of the putative adhesion molecule endoglin by macrophages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537377     DOI: 10.1002/eji.1830220216

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  59 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Authors:  Anna R Kwilas; Renee N Donahue; Kwong Y Tsang; James W Hodge
Journal:  Cancer Cell Microenviron       Date:  2015

4.  Isolation and characterization of high endothelial cell lines derived from mouse lymph nodes.

Authors:  J M Cook-Mills; J S Gallagher; T L Feldbush
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

5.  Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia.

Authors:  Sun K Kim; Roberto Romero; Zeynep A Savasan; Yi Xu; Zhong Dong; Deug-Chan Lee; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  Am J Reprod Immunol       Date:  2012-12-24       Impact factor: 3.886

6.  Expression of normal and truncated forms of human endoglin.

Authors:  U Raab; B Velasco; P Lastres; A Letamendía; C Calés; C Langa; E Tapia; J P López-Bote; E Páez; C Bernabéu
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

7.  Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction.

Authors:  Franck Lebrin; Marie-José Goumans; Leon Jonker; Rita L C Carvalho; Gudrun Valdimarsdottir; Midory Thorikay; Christine Mummery; Helen M Arthur; Peter ten Dijke
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

8.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

9.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

10.  Visualizing HIF-1α mRNA in a Subpopulation of Bone Marrow-Derived Cells to Predict Retinal Neovascularization.

Authors:  Md Imam Uddin; Tyler C Kilburn; Craig L Duvall; John S Penn
Journal:  ACS Chem Biol       Date:  2020-10-20       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.